{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:00:32Z","timestamp":1760014832231,"version":"3.37.3"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2018YSKY0017-9"],"award-info":[{"award-number":["2018YSKY0017-9"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Objective<\/jats:title><jats:p>To prospectively establish an early diagnosis model of acute colon cancerous bowel obstruction by applying nuclear magnetic resonance hydrogen spectroscopy(1H NMR) technology based metabolomics methods, combined with machine learning.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>In this study, serum samples of 71 patients with acute bowel obstruction requiring emergency surgery who were admitted to the Emergency Department of Sichuan Provincial People\u2019s Hospital from December 2018 to November 2020 were collected within 2 hours after admission, and NMR spectroscopy data was taken after pretreatment. After postoperative pathological confirmation, they were divided into colon cancerous bowel obstruction (CBO) group and adhesive bowel obstruction (ABO) control group. Used MestReNova software to extract the two sets of spectra bins, and used the MetaboAnalyst5.0 website to perform partial least square discrimination (PLS-DA), combining the human metabolome database (HMDB) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) to find possible different Metabolites and related metabolic pathways.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>22 patients were classified as CBO group and 30 were classified as ABO control group. Compared with ABO group, the level of Xanthurenic acid, 3-Hydroxyanthranilic acid, Gentisic acid, Salicyluric acid, Ferulic acid, Kynurenic acid, CDP, Mandelic acid, NADPH, FAD, Phenylpyruvate, Allyl isothiocyanate, and Vanillylmandelic acid increased in the CBO group; while the lecel of L-Tryptophan and Bilirubin decreased. There were significant differences between two groups in the tryptophan metabolism, tyrosine metabolism, glutathione metabolism, phenylalanine metabolism and synthesis pathways of phenylalanine, tyrosine and tryptophan (all P&lt;0.05). Tryptophan metabolism pathway had the greatest impact (Impact = 0.19). The early diagnosis model of colon cancerous bowel was established based on the levels of six metabolites: Xanthurenic acid, 3-Hydroxyanthranilic acid, Gentisic acid, Salicylic acid, Ferulic acid and Kynurenic acid (R2 = 0.995, Q2 = 0.931, RMSE = 0.239, AUC = 0.962).<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusion<\/jats:title><jats:p>This study firstly used serum to determine the difference in metabolome between patients with colon cancerous bowel obstruction and those with adhesive bowel obstruction. The study found that the metabolic information carried by the serum was sufficient to discriminate the two groups of patients and provided the theoretical supporting for the future using of the more convenient sample for the differential diagnosis of patients with colon cancerous bowel obstruction. Quantitative experiments on a large number of samples were still needed in the future.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0266730","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T17:26:35Z","timestamp":1660670795000},"page":"e0266730","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Establishment of an early diagnosis model of colon cancerous bowel obstruction based on 1H NMR"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-8423","authenticated-orcid":true,"given":"Jie","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8904-455X","authenticated-orcid":true,"given":"Jin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengchi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daolin","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"issue":"5","key":"pone.0266730.ref001","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"J Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"4","key":"pone.0266730.ref002","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s005200000198","article-title":"Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer","volume":"9","author":"C Ripamonti","year":"2001","journal-title":"Support Care Cancer"},{"issue":"1 Suppl","key":"pone.0266730.ref003","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jpainsymman.2007.04.011","article-title":"Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction","volume":"34","author":"T Anthony","year":"2007","journal-title":"J Pain Symptom Manage"},{"key":"pone.0266730.ref004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40170-016-0151-y","article-title":"Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool","volume":"4","author":"DG Brown","year":"2016","journal-title":"Cancer Metab"},{"issue":"3","key":"pone.0266730.ref005","doi-asserted-by":"crossref","first-page":"e0152126","DOI":"10.1371\/journal.pone.0152126","article-title":"Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations","volume":"11","author":"R Sinha","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"pone.0266730.ref006","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/carcin\/bgu131","article-title":"Fecal metabolomics: assay performance and association with colorectal cancer","volume":"35","author":"JJ Goedert","year":"2014","journal-title":"Carcinogenesis"},{"issue":"3","key":"pone.0266730.ref007","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/nbm.1345","article-title":"Metabolite profiling of fecal water extracts from human colorectal cancer","volume":"22","author":"D Monle\u00f3n","year":"2009","journal-title":"NMR Biomed"},{"issue":"8","key":"pone.0266730.ref008","doi-asserted-by":"crossref","first-page":"e70803","DOI":"10.1371\/journal.pone.0070803","article-title":"Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults","volume":"8","author":"TL Weir","year":"2013","journal-title":"PLoS One"},{"issue":"20","key":"pone.0266730.ref009","doi-asserted-by":"crossref","first-page":"29454","DOI":"10.18632\/oncotarget.8762","article-title":"NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer","volume":"7","author":"Y Lin","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"pone.0266730.ref010","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.3892\/etm.2017.4367","article-title":"Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals","volume":"13","author":"X Wang","year":"2017","journal-title":"Exp Ther Med"},{"issue":"8","key":"pone.0266730.ref011","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/chromsci\/bmx046","article-title":"UPLC-Q-TOF\/MS-Based Metabolic Profiling Comparison of Two Major Bioactive Components and Their Metabolites in Normal and CKD Rat Plasma, Urine and Feces Following Oral Administration of Fructus Corni Extract","volume":"55","author":"M Zhao","year":"2017","journal-title":"J Chromatogr Sci"},{"issue":"2","key":"pone.0266730.ref012","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1021\/pr201001a","article-title":"Distinct urinary metabolic profile of human colorectal cancer","volume":"11","author":"Y Cheng","year":"2012","journal-title":"J Proteome Res"},{"issue":"9","key":"pone.0266730.ref013","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1021\/pr500443c","article-title":"Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery","volume":"13","author":"Y Ni","year":"2014","journal-title":"J Proteome Res"},{"issue":"4","key":"pone.0266730.ref014","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4161\/cbt.27625","article-title":"Non-invasive fecal metabonomic detection of colorectal cancer","volume":"15","author":"LC Phua","year":"2014","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"pone.0266730.ref015","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1021\/pr9004162","article-title":"Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS","volume":"8","author":"Y Qiu","year":"2009","journal-title":"J Proteome Res"},{"issue":"4","key":"pone.0266730.ref016","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/anie.201804736","article-title":"High-Throughput Metabolomics by 1D NMR","volume":"58","author":"A Vignoli","year":"2019","journal-title":"Angew Chem Int Ed Engl"},{"author":"P.G. Takis","journal-title":"Trends in Analytical Chemistry","article-title":"Uniqueness of the NMR approach to metabolomics","key":"pone.0266730.ref017"},{"issue":"6","key":"pone.0266730.ref018","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1021\/pr400337b","article-title":"Metabonomics identifies serum metabolite markers of colorectal cancer","volume":"12","author":"B Tan","year":"2013","journal-title":"J Proteome Res"},{"issue":"3","key":"pone.0266730.ref019","first-page":"1093","article-title":"Biomarkers in Colorectal Cancer","volume":"36","author":"AJ Yiu","year":"2016","journal-title":"Anticancer Res"},{"issue":"4","key":"pone.0266730.ref020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s11912-009-0042-2","article-title":"Current concepts in malignant bowel obstruction management","volume":"11","author":"E Roeland","year":"2009","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"pone.0266730.ref021","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.3390\/ijms19113288","article-title":"Fingerprinting Acute Digestive Diseases by Untargeted NMR Based Metabolomics","volume":"19","author":"PG Takis","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"8","key":"pone.0266730.ref022","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1590\/s0102-865020170080000006","article-title":"Bacterial translocation and mortality on rat model of intestinal ischemia and obstruction","volume":"32","author":"RIDD Costa","year":"2017","journal-title":"Acta Cir Bras"},{"issue":"3","key":"pone.0266730.ref023","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.tips.2017.11.007","article-title":"Targeting the IDO1\/TDO2-KYN-AhR Pathway for Cancer Immunotherapy\u2014Challenges and Opportunities","volume":"39","author":"JE Cheong","year":"2018","journal-title":"Trends Pharmacol Sci"},{"issue":"26","key":"pone.0266730.ref024","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood.2019001675","article-title":"Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor-tissue factor axis","volume":"134","author":"M Belghasem","year":"2019","journal-title":"Blood"},{"issue":"4","key":"pone.0266730.ref025","doi-asserted-by":"crossref","first-page":"e0122046","DOI":"10.1371\/journal.pone.0122046","article-title":"Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers","volume":"10","author":"P Puccetti","year":"2015","journal-title":"PLoS One"},{"key":"pone.0266730.ref026","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.4049\/jimmunol.170.12.5809","article-title":"Tryptophan catabolism and regulation of adaptive immunity","volume":"170","author":"AL Mellor","year":"2003","journal-title":"J Immunol"},{"key":"pone.0266730.ref027","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fimmu.2020.00388","article-title":"IDO and Kynurenine Metabolites in Peripheral and CNS Disorders","volume":"11","author":"YS Huang","year":"2020","journal-title":"Front Immunol"},{"key":"pone.0266730.ref028","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev-nutr-071714-034330","article-title":"Direct and Functional Biomarkers of Vitamin B6 Status","volume":"35","author":"PM Ueland","year":"2015","journal-title":"Annu Rev Nutr"},{"issue":"7","key":"pone.0266730.ref029","first-page":"1320","article-title":"Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer","volume":"21","author":"RA de Jong","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"pone.0266730.ref030","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4156","article-title":"Simultaneous determination of tryptophan, kynurenine, kynurenic acid, xanthurenic acid and 5-hydroxytryptamine in human plasma by LC-MS\/MS and its application to acute myocardial infarction monitoring","volume":"32","author":"Q Tong","year":"2018","journal-title":"Biomed Chromatogr"},{"issue":"2","key":"pone.0266730.ref031","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1074\/jbc.C115.680488","article-title":"Tetrahydrobiopterin Biosynthesis as a Potential Target of the Kynurenine Pathway Metabolite Xanthurenic Acid","volume":"291","author":"H Haruki","year":"2016","journal-title":"J Biol Chem"},{"issue":"Pt B","key":"pone.0266730.ref032","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuropharm.2016.06.020","article-title":"Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors","volume":"112","author":"F Fazio","year":"2017","journal-title":"Neuropharmacology"},{"key":"pone.0266730.ref033","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0301-0082(00)00032-0","article-title":"Kynurenines in the CNS: from endogenous obscurity to therapeutic importance","volume":"64","author":"TW Stone","year":"2001","journal-title":"Prog Neurobiol"},{"issue":"1","key":"pone.0266730.ref034","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2982.2007.00989.x","article-title":"Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs","volume":"20","author":"J Kaszaki","year":"2008","journal-title":"Neurogastroenterol Motil"},{"issue":"7368","key":"pone.0266730.ref035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"CA Opitz","year":"2011","journal-title":"Nature"},{"issue":"4","key":"pone.0266730.ref036","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.4049\/jimmunol.1300497","article-title":"The aryl hydrocarbon receptor promotes IL-10 production by NK cells","volume":"192","author":"S Wagage","year":"2014","journal-title":"J Immunol"},{"issue":"4","key":"pone.0266730.ref037","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.18632\/oncotarget.1637","article-title":"Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR","volume":"5","author":"UM Litzenburger","year":"2014","journal-title":"Oncotarget"},{"key":"pone.0266730.ref038","doi-asserted-by":"crossref","first-page":"2371895","DOI":"10.1155\/2017\/2371895","article-title":"3-Hydroxykynurenine and 3-Hydroxyanthranilic Acid Enhance the Toxicity Induced by Copper in Rat Astrocyte Culture","volume":"2017","author":"D Ram\u00edrez-Ortega","year":"2017","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"pone.0266730.ref039","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.ajpath.2011.05.048","article-title":"The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1","volume":"179","author":"D Krause","year":"2011","journal-title":"Am J Pathol"},{"key":"pone.0266730.ref040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.imlet.2010.05.008","article-title":"Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSH depletion","volume":"132","author":"SM Lee","year":"2010","journal-title":"Immunol Lett"},{"issue":"5749","key":"pone.0266730.ref041","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1117634","article-title":"Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite","volume":"310","author":"M Platten","year":"2005","journal-title":"Science"},{"issue":"16","key":"pone.0266730.ref042","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/eurheartj\/ehs175","article-title":"The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice","volume":"33","author":"L Zhang","year":"2012","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0266730.ref043","first-page":"20","article-title":"Aspirin metabolites 2,3-DHBA and 2,5-DHBA inhibit cancer cell growth: Implications in colorectal cancer prevention","volume":"21","author":"R ankaranarayanan","year":"2020","journal-title":"Mol Med Rep"},{"issue":"2","key":"pone.0266730.ref044","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cpt1974152111","article-title":"Orthohydroxyhippuric (salicyluric) acid\u2014its physiologic and clinical significance","volume":"15","author":"MD Altschule","year":"1974","journal-title":"Clin Pharmacol Ther"},{"issue":"2\u20133","key":"pone.0266730.ref045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.biopha.2006.07.094","article-title":"Suppressive effect of post- or pre-treatment of aspirin metabolite on mitomycin C-induced genotoxicity using the somatic mutation and recombination test in Drosophila melanogaster","volume":"61","author":"M Niikawa","year":"2007","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"pone.0266730.ref046","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1872213X13666190621125048","article-title":"Ferulic Acid: A Promising Therapeutic Phytochemical and Recent Patents Advances","volume":"13","author":"A Chaudhary","year":"2019","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"issue":"1\u20132","key":"pone.0266730.ref047","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11010-019-03606-8","article-title":"A novel compound, ferulic acid-bound resveratrol, induces the tumor suppressor gene p15 and inhibits the three-dimensional proliferation of colorectal cancer cells","volume":"462","author":"Y Sawata","year":"2019","journal-title":"Mol Cell Biochem"},{"issue":"20","key":"pone.0266730.ref048","doi-asserted-by":"crossref","first-page":"11962","DOI":"10.1021\/acs.analchem.8b02412","article-title":"Quantitative Lipoprotein Subclass and Low Molecular Weight Metabolite Analysis in Human Serum and Plasma by 1H NMR Spectroscopy in a Multilaboratory Trial","volume":"90","author":"B Jim\u00e9nez","year":"2018","journal-title":"Anal Chem"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T21:07:08Z","timestamp":1700946428000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0266730"}},"subtitle":[],"editor":[{"given":"Oscar","family":"Millet","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0266730","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,8,16]]}}}